Philips Extends its Mobile C-arm Range with Zenition 30, Alleviating Staff Shortages by Empowering Surgeons with Greater Personalization and Control

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 3000 – Zenition 30 [1], the latest addition to the company’s highly versatile Zenition mobile C-arm series. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures.

The Zenition 30 gives surgeons a greater level of control, empowering them to work more autonomously and independently. By reducing dependency on support staff, Zenition 30 helps alleviate the staff shortages faced by many hospitals, while its workflow-enhancing features and excellent image quality allow surgeons to deliver high-quality care to more patients. The launch of the Zenition 30 follows the recent launch of the Philips Zenition 10 C-arm [2].

“Based on our Zenition platform’s proven ease of use and workflow efficiency, the new Zenition 30 offers a unique combination of personalized control and image clarity to enhance the speed and accuracy of decision-making for a range of clinical procedures at a price point that meets today’s economic and business goals,” said Mark Stoffels, General Manager, Philips Image Guided Therapy Systems.

High-quality imaging

Zenition 30 offers versatility for a range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures. Featuring Philips’ latest-generation flat detector technology, advanced imaging algorithms, and personalized user profiles, the new system delivers superior image quality, dose efficiency, and workflow customization. From the moment a surgeon logs on, the Zenition 30 automatically adjusts to their preferred settings and way of working, contributing to fewer manual adjustments and more first-time-right imaging. In addition to rapid set-up and protocol selection, the Zenition 30 also offers surgeons much greater control over C-arm positioning during surgical procedures.

In independent usability studies involving clinicians around the world who were offered hands-on experience of the Zenition 30 in simulated environments, 95% said they believed its enhanced surgeon control would allow them to work independently [3], while 84% believed that Zenition 30’s personalized image quality profiles meant fewer images might be needed during a procedure because the first image already incorporates their preferred settings [4].

As part of its commitment to doing business sustainably and helping its customers make responsible choices, Philips has designed the Zenition 30 to have a 25% increased product lifetime [5] and also has a refurbished program available, making it ‘circular-ready’ for repair, refurbishment, and recycling [5].

Other C-arm systems in Philips’ Zenition series are the Zenition 50, Zenition 70, and the recently launched Zenition 10 [2].

[1] Zenition 30 mobile C-arm systems are available for sale in a limited number of countries. Please check with a local representative for availability in your market. Pending 510 (k) not available for sale in the USA.
[2] Zenition 10 mobile C-arm system is not available in the USA.
[3] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 37 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.
[4] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 50 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.

[5] Compared to its predecessor, BV Endura 2.3.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version